RxDoctor Payments Data

Greg Wilkinson, PA

Physician Assistant · Sacramento, CANPI 1316146939

Payments from drug & device makers

$4,234in general payments, 2019–2025

Across 94 payments — averaging $45.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$2K
  • AbbVie$666
  • Nevro Corp.$225
  • Medtronic$210
  • Biohaven Pharmaceutical Holding Company Ltd.$111
  • GRT US Holding, Inc.$111
  • plus $683 from 16 others

What the payments were for

  • Travel & lodging$1,95546%
  • Food & beverage$2,26554%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,234 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$236,163
Medicare patients
246
Services billed
5,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl32$37,166
Xtampza ErOxycodone Myristate33$17,877
Oxycodone Hcl445$13,397
LinzessLinaclotide12$11,480
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen229$6,998
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$6,014
Morphine Sulfate ErMorphine Sulfate184$4,699
MovantikNaloxegol Oxalate12$4,670
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen128$3,996
Lidocaine20$3,563
Gabapentin129$3,539
ValiumDiazepam11$3,045
Lubiprostone13$2,493
Methadone Hcl101$2,283
Tramadol Hcl ErTramadol Hcl20$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$88$17,87733 claims
AbbVieLinzess$666$11,48012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →